Health Minister Harshvardhan to speak on India's efforts to develop Covid-19 vaccine

The human clinical trials of the Oxford-AstraZeneca vaccine, which is also known as 'Covishield' in India, have been running smoothly in India and have not shown any adverse side-effects so far. The coronavirus vaccine, Covishield, is currently in Phase 2 and Phase 3 human clinical trials in the country.

The phase-III human clinical trial of the coronavirus vaccine being developed by Oxford University, and manufactured by the Serum Institute of India (SII), began at the Sassoon General Hospital in Pune on September 17. King Edward Memorial (KEM) Hospital in Mumbai on September 23 began the phase II and III trials of the coronavirus vaccine.